Dishman Carbogen Amcis Ltd - 540701 - Statement Of Investor Complaints For The Quarter Ended June 2022
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 3030 Name of the Signatory :- Shrima DaveDesignation :- Company Secretary and Compliance Officer Dishman Carbogen Amcis Ltd - 540701 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We submit herewith the confirmation certificate received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent (RTA) as per regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March, 2022. Dishman Carbogen Amcis Ltd - 540701 - Closure of Trading Window
We would like to inform that as per Code of Conduct for prevention of Insider Trading adopted by the Company under SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, the Trading Window for dealing in securities/ shares of the Company shall remain closed with effect from 1st July, 2022 for all the Directors, Designated Persons and their immediate relative(s). The Trading Window will be opened 48 hours after the announcement of the Un-Audited Financial Results of the Company for the quarter ended 30th June, 2022. Dishman Carbogen Amcis Ltd - 540701 - Announcement under Regulation 30 (LODR)-Newspaper Publication
We are pleased to enclose herewith the copies of newspaper advertisement published on 23rd June, 2022 in 'Indian Express' in its English edition and in 'Financial Express' in its Gujarati edition daily newspapers regarding intimation of transfer of Equity Shares of the Company to Investor Education and Protection Fund (IEPF) after the due date pursuant to the provisions of the Investor Education and Protection Fund Authority (Accounting, Audit, Transfer and Refund) Rules, 2016 ("the IEPF Rules"). Dishman Carbogen Amcis Ltd - 540701 - Compliances-Reg.24(A)-Annual Secretarial Compliance
Pursuant to Regulation 24A of SEBI (LODR) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD1/27/2019 dated February 8, 2019, please find enclosed the Annual Secretarial Compliance Report for the year ended March 31, 2022, issued by Mr. Ashok P. Pathak & Co., Practicing Company Secretaries. Dishman Carbogen Amcis Ltd - 540701 - DISCLOSURES OF RELATED PARTY TRANSACTIONS PURSUANT TO REGULATION 23 (9) OF THE SEBI (LISTING OBLIGATIONS AND DISCLOSURES REQUIREMENTS) REGULATIONS, 2015
Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose disclosure of Related Party Transactions of the Company on a consolidated basis, in the format specified under SEBI Circular bearing reference no. SEBI/HO/CFD/CMD1/CIR/P/ 2021/662 dated November 22, 2021 for the half year ended March 31, 2022. Dishman Carbogen Amcis Ltd - 540701 - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, pls. find enclosed herewith transcript of earnings conference call arranged by the Company with Investors on Wednesday, 11th May, 2022 to discuss the financial result and performance of the Company for the quarter and year ended on 31st March, 2022. The aforesaid transcript is also being hosted on the website of the Company, www.imdcal.com in accordance with the Regulation 46 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015. Dishman Carbogen Amcis Ltd - 540701 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
The audio recording of Conference Call arranged by the Company with Investors on Wednesday, 11th May, 2022 at 16.00 hrs. (IST) to discuss the financial result and performance of the Company for the quarter and year ended on 31st March, 2022 is available on the Company's website at https://imdcal.com/images/files/Investor-Relations/Investor%20Call/Audio-Video%20Recording/2021-22/Q4%20Result%20-%20Audio%20Recording%20-%2011.05.2022.mp3 Q4FY22 Quarterly Result Announced for Dishman Carbogen Amcis Ltd.
Pharmaceuticals firm Dishman Carbogen Amcis declares Q4FY22 result: Net Revenue at Rs 5,689.9 mn in Q4 FY22 up by 7.5% YoY CRAMS revenue increased by 15.9% YoY primarily due to: CRAMS India revenue increased by 114.0% due to continuous increase in commercial supplies from India. Marketable Molecules revenue decreased by 15.3% YoY primarily due to: Carbogen Amcis BV revenue decreased by 13.0% on account of lower sales of Vitamin D analogues Others revenue decreased by 17.7% due to lower sales of quats and intermediates EBITDA Margin at 3.9% in Q4 FY22 compared to 16.7% in Q4 FY21 due to: CGAM revenues were driven hugely by lower margin development revenues. One-time provisions also hit the margins adversely Power and fuel and logistics costs increased across all entities Increased costs shall be passed on to customers once the contracts/orders are renegotiated, hence there is a timing lag. Net Debt excluding lease liabilities was USD 122.7 mn as on March 31, 2022 (USD 121.9 mn as on December 31, 2021). Capital expenditure for Q4 FY22 was approximately USD 9.4 mn and for full year FY22 was approximately USD 61.2 mn Construction of the future dedicated manufacturing building for a Japanese Client for a novel oncology drug linker is progressing, this is well aligned with Customer program. Some advanced intermediated for a US customer has been out-licensed to other US customers We currently run 17 phase III projects, 5 of them are in the very final stage. These projects span therapeutic areas such as antibacterial infection, lymphoma, multiple myeloma, myeloid leukemia, hypersimplex and gastric related disease. 1 additional early phase III project has moved into the late phase arena during Q4 FY2021. Our highly complex GMP precursor for a commercial oncology product for a Japan based client will be manufactured on a yearly basis by CGAM. The flow of inquiries has been strong and consistent over last fiscal. In Europe, the Development Pipeline stands at CHF 106.1 mn as of March 31st , 2022 Result PDF Dishman Carbogen Amcis Ltd - 540701 - Announcement under Regulation 30 (LODR)-Investor Presentation
Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, kindly find enclosed herewith Presentation on financial result for the quarter and year ended 31st March, 2022 to be made to Analyst and Investors. The aforesaid presentation is also being hosted on the website of the Company, www.imdcal.com in accordance with the Regulation 46 of the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015.